These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37174986)

  • 1. Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET).
    Lamberti G; Prinzi N; Bongiovanni A; Torniai M; Andrini E; Biase D; Malvi D; Mosca M; Berardi R; Ibrahim T; Pusceddu S; Campana D
    Diagnostics (Basel); 2023 Apr; 13(9):. PubMed ID: 37174986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors.
    Liu AJ; Ueberroth BE; McGarrah PW; Buckner Petty SA; Kendi AT; Starr J; Hobday TJ; Halfdanarson TR; Sonbol MB
    Oncologist; 2021 May; 26(5):383-388. PubMed ID: 33496040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide Receptor Radionuclide Therapy versus Capecitabine/Temozolomide for the Treatment of Metastatic Pancreatic Neuroendocrine Tumors.
    Gujarathi R; Tobias J; Abou Azar S; Keutgen XM; Liao CY
    Cancers (Basel); 2024 Aug; 16(17):. PubMed ID: 39272851
    [No Abstract]   [Full Text] [Related]  

  • 4. MEN1/DAXX/ATRX mutations enhance progression-free survival in gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy.
    Gujarathi R; Abou Azar S; Tobias J; Polite BN; Setia N; Feinberg N; Appelbaum DE; Keutgen XM; Liao CY
    Endocr Relat Cancer; 2024 Nov; 31(11):. PubMed ID: 39093924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors.
    Nicolini S; Bodei L; Bongiovanni A; Sansovini M; Grassi I; Ibrahim T; Monti M; Caroli P; Sarnelli A; Diano D; Di Iorio V; Grana CM; Cittanti C; Pieri F; Severi S; Paganelli G
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3260-3267. PubMed ID: 33604690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical outcomes of gastro-entero-pancreatic neuroendocrine tumors G3 versus neuroendocrine carcinoma.
    Li MX; Lopez-Aguiar AG; Poultsides G; Rocha F; Weber S; Fields R; Idrees K; Cho C; Maithel SK; Zhang XF; Pawlik TM
    J Surg Oncol; 2022 Sep; 126(4):689-697. PubMed ID: 35616186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive genomic and transcriptomic characterization of high-grade gastro-entero-pancreatic neoplasms.
    Angerilli V; Sabella G; Simbolo M; Lagano V; Centonze G; Gentili M; Mangogna A; Coppa J; Munari G; Businello G; Borga C; Schiavi F; Pusceddu S; Leporati R; Oldani S; Fassan M; Milione M
    Br J Cancer; 2024 Jul; 131(1):159-170. PubMed ID: 38729995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter Analysis of Treatment Outcomes for Systemic Therapy in Well Differentiated Grade 3 Neuroendocrine Tumors (NET G3).
    Apostolidis L; Dal Buono A; Merola E; Jann H; Jäger D; Wiedenmann B; Winkler EC; Pavel M
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33923759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review.
    Zappi A; Persano I; Galvani L; Parlagreco E; Andrini E; Campana D; Brizzi MP; Lamberti G; La Salvia A
    J Clin Med; 2023 Jan; 12(2):. PubMed ID: 36675645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: A "Real-World" Data Analysis.
    Bongiovanni A; Liverani C; Foca F; Fausti V; Di Menna G; Mercatali L; De Vita A; Riva N; Calpona S; Miserocchi G; Spadazzi C; Cocchi C; Ibrahim T
    Neuroendocrinology; 2021; 111(9):895-906. PubMed ID: 33221806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant Expression of Long Non Coding RNA HOTAIR and De-Regulation of the Paralogous 13 HOX Genes Are Strongly Associated with Aggressive Behavior of Gastro-Entero-Pancreatic Neuroendocrine Tumors.
    Di Mauro A; Scognamiglio G; Aquino G; Cerrone M; Liguori G; Clemente O; Di Bonito M; Cantile M; Botti G; Tafuto S; Tatangelo F
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34208964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastroenteropancreatic grade 3 neuroendocrine tumors: a single entity or a heterogeneous group? A retrospective analysis.
    Laffi A; Spada F; Bagnardi V; Frassoni S; Pisa E; Rubino M; Barberis M; Fazio N
    J Endocrinol Invest; 2022 Feb; 45(2):317-325. PubMed ID: 34282554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Well differentiated grade 3 gastroenteropancreatic neuroendocrine tumors:new insights into diagnosis and therapeutic strategy].
    Fan ZY; Shi M; Yang J; Li YZ; Su P; Wang X; Zhan HX
    Zhonghua Wai Ke Za Zhi; 2021 Aug; 59(8):704-710. PubMed ID: 34192864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective Evaluation of
    Brighi N; Lamberti G; Andrini E; Mosconi C; Manuzzi L; Donati G; Lisotti A; Campana D
    Curr Oncol; 2023 Jan; 30(2):1381-1394. PubMed ID: 36826067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review.
    Chan DL; Bergsland EK; Chan JA; Gadgil R; Halfdanarson TR; Hornbacker K; Kelly V; Kunz PL; McGarrah PW; Raj NP; Reidy DL; Thawer A; Whitman J; Wu L; Becker C; Singh S
    Oncologist; 2021 Nov; 26(11):950-955. PubMed ID: 34342086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
    Ducreux M; Bennouna J; Hebbar M; Ychou M; Lledo G; Conroy T; Adenis A; Faroux R; Rebischung C; Bergougnoux L; Kockler L; Douillard JY;
    Int J Cancer; 2011 Feb; 128(3):682-90. PubMed ID: 20473862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastroenteropancreatic neuroendocrine neoplasms G3: Novel insights and unmet needs.
    Shi M; Fan Z; Xu J; Yang J; Li Y; Gao C; Su P; Wang X; Zhan H
    Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188637. PubMed ID: 34678439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.
    Carlsen EA; Fazio N; Granberg D; Grozinsky-Glasberg S; Ahmadzadehfar H; Grana CM; Zandee WT; Cwikla J; Walter MA; Oturai PS; Rinke A; Weaver A; Frilling A; Gritti S; Arveschoug AK; Meirovitz A; Knigge U; Sorbye H
    Endocr Relat Cancer; 2019 Feb; 26(2):227-239. PubMed ID: 30540557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations.
    Elvebakken H; Perren A; Scoazec JY; Tang LH; Federspiel B; Klimstra DS; Vestermark LW; Ali AS; Zlobec I; Myklebust TÅ; Hjortland GO; Langer SW; Gronbaek H; Knigge U; Tiensuu Janson E; Sorbye H
    Neuroendocrinology; 2021; 111(9):883-894. PubMed ID: 33002892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol.
    Bongiovanni A; Liverani C; Pusceddu S; Leo S; Di Meglio G; Tamberi S; Santini D; Gelsomino F; Pucci F; Berardi R; Lolli I; Bergamo F; Ricci S; Foca F; Severi S; Ibrahim T;
    BMJ Open; 2020 Jul; 10(7):e034393. PubMed ID: 32690499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.